

(12) **UK Patent Application** (19) **GB** (11) **2462561** (13) **A**

(43) Date of Printing by UK Office **17.02.2010**

(21) Application No: **0921330.7**

(22) Date of Filing: **19.05.2008**

(30) Priority Data:
(31) **11802059** (32) **18.05.2007** (33) **US**

(86) International Application Data:
PCT/US2008/006368 En 19.05.2008

(87) International Publication Data:
WO2008/144020 En 27.11.2008

(71) Applicant(s):
**Lifeline Scientific, Inc.
2570 East Devon Avenue, Des Plaines 60018, Illinois,
United States of America**

(72) Inventor(s):
**Christopher Curtis
John Brassil
David Kravitz**

(74) Agent and/or Address for Service:
**Gill Jennings & Every LLP
Broadgate House, 7 Eldon Street, LONDON,
EC2M 7LH, United Kingdom**

(51) INT CL:
G01N 33/50 (2006.01)

(56) Documents Cited by ISA:
**WO 2005/074681 A US 6197575 A
US 20070072222 A US 20060019326 A
Am J Physiol: Heart Circulat Physiol; Vol 289, pp
H37-H47 (2005). Tokarska-Schlattner et al. "Acute
toxicity of doxorubicin on isolated perfused heart:
response of kinases regulating energy supply"**

(58) Field of Search by ISA:
INT CL **G01N**
Other: **WPI DATA, EPO-INTERNAL**

(54) Abstract Title: **Ex vivo methods for testing organ system disruption**

(57) Properties such as toxicity of substances may be determined by assaying properties, fates and effects of substances in an ex vivo metabolically active human organ or tissue under normothermic perfusion with a fluid containing a test substance. The data can be used as, for example, part of a submission to a government regulatory organization. Preferred methods use perfused endocrine gland organs or tissues to evaluate hormone or other bodily chemical disruption caused by substances and pre-donation diseased or injured organs or tissues.

GB 2462561 A